Acorda Therapeutics Announces Commercial Launch of INBRIJA™ (levodopa inhalation powder)
Acorda Therapeutics, Inc. (ACOR)
Last acorda therapeutics, inc. earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
acorda.com/investors
Company Research
Source: Business Wire
First and Only FDA-Approved Inhaled Levodopa for On-demand Use for OFF Periods in People with Parkinson’s Taking Carbidopa/Levodopa ARDSLEY, N.Y.--(BUSINESS WIRE)-- Acorda Therapeutics, Inc. (NASDAQ: ACOR) today announced that INBRIJA is now available by prescription in the United States. INBRIJA was approved by the U.S. Food and Drug Administration (FDA) on December 21, 2018 for intermittent treatment in people with Parkinson’s taking carbidopa/levodopa who experience OFF episodes. “OFF periods are extremely disruptive for those living with Parkinson’s. We are excited that INBRIJA is now available to address this important unmet medical need, and that prescriptions are already being filled,” said Ron Cohen, M.D., Acorda’s President and CEO. “Our field sales and medical teams have been meeting with Movement Disorder specialists to educate them about INBRIJA and our Prescription Support Services c
Show less
Read more
Impact Snapshot
Event Time:
ACOR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACOR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACOR alerts
High impacting Acorda Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ACOR
News
- Acorda Therapeutics, Inc. (NASDAQ: ACOR) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.MarketBeat
- Acorda Therapeutics, Inc. (NASDAQ: ACOR) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.MarketBeat
- Acorda Therapeutics Announces Nasdaq Delisting Notification [Yahoo! Finance]Yahoo! Finance
- Acorda Therapeutics Announces Nasdaq Delisting NotificationBusiness Wire
- CALM,PLAY and VNDA are among after hour movers [Seeking Alpha]Seeking Alpha
ACOR
Sec Filings
- 4/4/24 - Form 8-K
- 3/13/24 - Form 8-K
- ACOR's page on the SEC website